Randomized controlled trials (RCTs) and systematic reviews are the most reliable methods of determining the eff ects of treatment. Th e randomization procedure gives a randomized controlled trial its strength. Random allocation means that all participants have the same chance of being assigned to each of the study groups. Th e choice of which end point(s) to select is critical to any study design. Intention-to-treat is the preferred approach to the analysis of clinical trials. Sample size calculations and data analyses have an important impact on the planning, interpretation, and conclusions of randomized trials. In this article, we discuss the problematic areas that can aff ect the outcome of a trial, such as blinding, sample size calculation, randomization; concealment allocation; intention of treating the analysis; selection of end points; selection of traditional versus equivalence testing, early stopped trials, selective publications.
INTRODUCTION
Randomized controlled trials (RCTs) and systematic reviews are the most reliable methods of determining the eff ects of treatment. Ideally, trials are designed and conducted both to minimize the bias (i. e. have a high internal validity) and to be relevant to a wide but defi ned population (i. e. have a high external validity, also termed generalizability). Th ere are problematic areas that can aff ect the outcome of a trial: blinding; sample size calculation, randomization; concealment allocation; intention to treat the analysis (the analytic method used); selection of end points; selection of traditional versus equivalence testing, early stopped trials, selection of publications. In our review, we address the questions such as what it is that leads the RCT to the highest level of evidence and what the features of the RCT that render it so useful are. In the article, we discuss a number of principles that answer these questions.
RESULTS AND DISCUSSION
Blinding in a clinical trial. Th e term "blinding" or "masking" refers to withholding information about the assigned interventions from people involved in the trial who may potentially be infl uenced by this knowledge. Blinding is an important safeguard against bias, particularly when assessing subjective outcomes. Blinding in a clinical trial can be defi ned as withholding information about treatment allocation from those who could potentially be infl uenced by this information. Unblinded studies exhibit an increased eff ect of treatment compared with blinded studies. In the section of methods, the authors should describe in some detail who was blinded, how they were blinded, and the success of blinding. Certainly participants and investigators can be blinded. Less commonly recognized is that data collectors and analysts should be blinded. Participants should be blinded because they may use other eff ective interventions, may report symptoms diff erently, or may drop out if they perceive they have received a placebo therapy. Investigators should be blinded because they may prescribe eff ective co-interventions, infl uence the follow-up, or patient reporting. Data collectors and analysts should be blinded because they may exhibit diff erent encouragement during performance testing, exhibit variable recordings of outcomes, or diff erent timing and frequency of outcome measurements. Th ere is no universal agreement on how to assess blinding or even whether it should be assessed. Study authors oft en ask investigators and participants to guess their treatment allocation and report the results. Some would suggest looking for bias-generating consequences instead of contamination and co-interventions. Th e measurement bias is defi ned as an inaccurate measurement due to either the accuracy of the measurement instrument or a bias based upon the expectations of participants and investigators. Blinding will help to limit measurement bias (1, 2) .
Randomization. Th e randomization procedure gives a randomized controlled trial its strength. Random allocation means that all participants have the same chance of being assigned to each of the study groups. Th e allocation, therefore, is not determined by the investigators, the clinicians, or the study participants. Th e purpose of random allocation of participants is to assure that the characteristics of the participants are as likely to be similar as possible across groups at the start of the comparison (also called the baseline). If randomization is done properly, it reduces the risk of a serious imbalance in the known and unknown factors that could infl uence the clinical course of the participants. No other study design allows investigators to balance these factors (1, 2) .
Concealment allocation. Aft er the randomization sequence is generated, the list may be given to the investigator responsible for enrolling participants in the study. Th is is referred to as unconcealed participant allocation. Th e investigator may steer participants to certain treatment arms based upon prognostic factors either consciously or unconsciously. Concealment allocation can be defi ned as the process by which the physician is blinded to the randomized sequence which was generated. Th e person who enrolls participants in the trial should not be the same person who generates the allocation sequence. In RCTs where concealment allocation has not been utilized, there is an overestimation of treatment effect compared to trials which conceal the allocation sequence. Th e treatment eff ect may increase by 20 to 30%. Th e average bias associated with the lack of adequate concealment allocation was less for outcomes that were evaluated objectively (death, ulcer closure) rather than subjectively (pain, patientreported outcomes) (1, 2) . Th e allocation concealment should not be confused with blinding. Allocation concealment seeks to prevent selection bias, protects the assignment sequence until allocation and can always be successfully implemented. In contrast, blinding seeks to prevent performance and ascertainment bias, protects the sequence aft er allocation, and cannot always be implemented. Without adequate allocation concealment, however, even random, unpredictable assignment sequences can be subverted.
Discrepancies in sample size calculations. Sample size calculations and data analysis have an important impact on the planning, interpretation, and conclusions of randomized trials. Statistical analysis oft en involves several subjective decisions about which data to include and which tests to use, producing potentially diff erent results and conclusions depending on the decisions taken. Th e methods of analysis that are chosen or altered aft er preliminary examination of the data can introduce bias if a subset of favourable results is then reported in a publication. Th e study protocol plays a key role in reducing such bias by documenting a pre-specifi ed blueprint for conducting and analyzing a trial. Explicit descriptions of methods before a trial starts help identify and deter unacknowledged, potentially biased changes made after reviewing the study results. To evaluate the completeness and consistency of reporting, we reviewed a comprehensive cohort of randomised trials and compared the sample size calculations and data analysis methods described in the protocols with those reported in the publications (3, 4) .
Superiority versus equivalence trials. Most trials test whether a new treatment is superior to a control (placebo) group or conventional standard of care. A superiority trial aims to demonstrate the superiority of a new therapy compared to an established therapy or placebo. In contrast, some trials are designed to show that a new treatment is not inferior to standard therapy by a predefi ned acceptable amount. Several problems challenge the design, conduct, analysis, reporting, and interpretation of noninferiority trials, and recent meta-analyses confi rm that the majority of published trials have substantial methodologic fl aws (5). As a result, potentially suboptimal treatments might be introduced into routine clinical practice. Other issues that are crucial to ensuring the validity of noninferiority inference, such as ethical considerations, adequate power, the quality of trial conduct, the choice of analytic strategy (intention-to-treat versus perprotocol), and an alternative Bayesian approach to analysis, are beyond the scope of this paper and have been detailed previously (6, 7). In conclusion, if noninferiority trials are to be applied to regulatory and clinical decisions about the marketing and use of new treatments, their assumptions must be made explicit, the criteria on which they are based must be suffi ciently justifi ed, and their infl uence on the resultant conclusions must be assessed rigorously and expressed unambiguously in published reports (8, 9) .
Intention-to-treat or on treatment analyses. Th ere are three general analytic approaches in clinical trials: analysis as randomized (referred to as intention-to-treat analysis, or ITT), compliers-only analysis (in which only those patients randomized to a treatment who completed the trial and complied with treatment are analyzed), and as-treated analysis (in which only those who received a given treatment are counted, whether or not the patient was initially assigned to that treatment). Intention-to-treat analysis is a method of analysis for randomized trials in which all patients randomly assigned to one of the treatments are analyzed together, regardless of whether or not they completed or received that treatment. Intention-to-treat analysis prevents a bias caused by the loss of participants, which may disrupt the baseline equivalence established by random assignment and which may refl ect non-adherence to the protocol. Intention-to-treat (ITT) analysis is commonly accepted as more conservative than the per-protocol (PP) restricted to the analysis of data on subjects who completed the study. Commonly, the within-groups diff erences being smaller in ITT than in PP, their statistical comparison leads to a smaller risk of type I error (i. e. inappropriately concluding a diff erence while there is not any). It also allows for keeping the randomization scheme (i. e. the balanced distribution of confounding factors) and thus not lead to a diff erential distribution of confounding factors among the groups if more subjects are withdrawn from the study in a given group (10) .
Surrogate outcomes. Th e choice of which end point(s) to select is critical to any study design. Two additional areas require particular attention: the use of surrogate measures and the use of composite end points. Th e most persuasive trials are ones that use clinical events or well-accepted surrogate variables as their outcomes. Trials with surrogate outcomes typically are smaller is size and therefore much less costly. Surrogate outcomes are oft en a measure of the underlying disease process (e. g., C-reactive protein), a measurement of preclinical disease (e. g., coronary artery calcifi cations), or an etiologically relevant, well-accepted risk factor (e. g., systolic BP, LDL cholesterol). Th e list of candidate surrogate outcomes is huge, but only a few are so well accepted that the trials that use these variables actually infl uence the policy. However, policy-making committees and bodies have not always been infl uenced by the results of trials with surrogate outcomes, because the clinical relevance of most surrogate outcomes is uncertain (11) (12) (13) (14) .
Subgroup or post-hoc analyses. Subgroup analyses are an important part of the analysis of a comparative clinical trial. However, they are commonly overinterpreted and can misguide further research or, worse, to result in suboptimal patient care. A randomized clinical trial is designed to determine whether a new treatment is more eff ective than an established one and assessed with a test, based on all randomized patients, of the null hypothesis that the treatments have equal effi cacy as measured in terms of the primary end point. Th en, subgroup analyses are conducted to assess whether diff erent types of patients respond diff erently to the new treatment. Th is sounds simple enough, but there are several important sources of confusion and uncertainty regarding such subgroup analysis. Clinicians should be wary of trials that report many subgroup analyses, unless the investigators provide valid reasons. Also, beware of trials that provide a small number of subgroup analyses. Th ey might have done many and just cherry-picked the interesting and signifi cant ones. Consequently, faulty reporting could mean that trials with few subgroup analyses are even worse than trials with many. Investigators fi nd more credence if they state that they reported all the analyses done. Furthermore, researchers should label non-prespecifi ed subgroup analyses as hypothesis-generating rather than confi rming. Such fi ndings should not appear in the conclusions. Clinicians should expect interaction tests for subgroup eff ects. Discount analyses are built on tests within subgroups. Even with a significant interaction test, readers should base the interpretation of the fi ndings on biological plausibility, on prespecifi cation of analyses, and on the statistical strength of the information. Generally, adjustments for multiplicity are unnecessary when investigators use interaction tests. However, in view of the frequently frivolous data-dredging pursuits involved, the argument for statistical adjustments is stronger than that for multiple endpoints. Moreover, if investigators do not use interaction tests and report tests on every individual subgroup, multiplicity adjustments are appropriate. Most subgroup fi ndings tend to exaggerate reality. Be especially suspicious of investigators highlighting a subgroup treatment eff ect in a trial with no overall treatment eff ect (15) (16) (17) (18) (19) .
RCTs stopped early for benefi t. When randomized clinical trials (RCTs) identify larger than expected treatment effects, investigators may conclude, before completing the trial as planned, that one treatment is superior to the other. Such trials oft en receive considerable attention. Clinicians face challenges when interpreting the results of truncated RCTs. Taking the point estimate of the treatment eff ect at face value will be misleading if the decision to stop the trial resulted from catching the apparent benefi t of treatment at a "random high". When this occurs, data from future trials will yield a more conservative estimate of treatment eff ect, the so-called regression to the truth eff ect. Th us, clinicians must attend not only to the usual methodological safeguards against bias, but also to the characteristics that aff ect the decision to stop a trial early. Such characteristics include the plausibility of the treatment eff ect, the planned sample size, the number of interim analyses aft er which the investigators stopped the RCT, and the statistical methods used to monitor the trial and to adjust estimates, p values, and confi dence intervals for interim analyses. While RCTs stopped early for reasons other than benefi t might share some characteristics with RCTs stopped early for benefi t, their implications are very diff erent. Trials stopped early because of harm or futility tend to result in a decreased use or prompt discontinuation of useless or potentially harmful interventions. In contrast, trials stopped early for benefi t may result in a rapid identifi cation, approval and dissemination of promising new treatments (20) (21) (22) (23) .
Selective publications. Another common problem is that the pharmaceutical industry can choose which data to publish and which to leave unavailable. Much has been written on eye-catching stories, such as the diffi culties in getting clear information about the number of suicide attempts in industry trials of SSRI antidepressants, or the number of heart attacks in patients on rofecoxib. Equally concerning is the routine grind of publication bias, where disappointing negative results on the benefi ts of treatments quietly disappear (24) . Medical decisions are based on the understanding of publicly reported clinical trials. If the evidence base is biased, then decisions based on this evidence may not be the optimal decisions. For example, selective publications of clinical trials and the outcomes within those trials, can lead to unrealistic estimates of drug eff ectiveness and alter the apparent riskbenefi t ratio. Attempts to study selective publications are complicated by the unavailability of data from unpublished trials. Researchers have found evidence for selective publication by comparing the results of published trials with information from surveys of authors, registries, institutional review boards, and funding agencies, and even with published methods. Numerous tests are available to detect a selectivereporting bias, but none are known to be capable of detecting or ruling out bias reliably (25-31).
CONCLUSIONS
Although RCTs remain a gold standard proof of effi cacy, there are many aspects of trial design that must be appropriately incorporated to ensure the value of a study. An inappropriate use of any tool (including RCTs) compromises the ability to meaningfully interpret the resulting information. We have presented several aspects should be considered by a user of the information when establishing the credence to attach to the information from a RCT.
